IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme

Gene

Volumn 554, Issue 1, 2015, Pages 81-86

  Kalkan, Rasime ^a,b   Atli, Emine Ikbal ^b,c   Özdemir, Muhsin ^b   Çiftçi, Evrim ^b   Aydin, Hasan Emre ^b   Artan, Sevilhan ^b   Arslantaş, Ali ^b  

^a NEAR EAST UNIVERSITY   (Turkey)

^b ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^c ACIBADEM UNIVERSITY   (Turkey)

Author keywords

IDH1 mutation; MGMT methylation; MS HRM; Primary glioblastoma

Indexed keywords

ARGININE; CYTOSINE; HISTIDINE; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENE MUTATION; GLIOBLASTOMA; HUMAN; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; WILD TYPE; AGE; BRAIN NEOPLASMS; EXON; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; TURKEY;

ADULT; AGE FACTORS; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; EXONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; TURKEY;

EID: 84912121230     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.10.027     Document Type: Article

References (29)

1. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008, 116(6):597-602. (Dec, Epub 2008 Nov 5.). 10.1007/s00401-008-0455-2.
2. Boots-Sprenger S.H., Sijben A., Rijntjes J., Tops B.B., Idema A.J., Rivera A.L., Bleeker F.E., Gijtenbeek A.M., Diefes K., Heathcock L., Aldape K.D., Jeuken J.W., Wesseling P. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod. Pathol. 2013, 26(7):922-929. (Jul). 10.1038/modpathol.2012.166. Epub 2013 Feb 22.
3. Carrillo J.A., Lai A., Nghiemphu P.L., Kim H.J., Phillips H.S., Kharbanda S., Moftakhar P., Lalaezari S., Yong W., Ellingson B.M., Cloughesy T.F., Pope W.B. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation and survival in glioblastoma. AJNR Am. J. Neuroradiol. 2012, 33(7):1349-1355. (Aug). 10.3174/ajnr.A2950. Epub 2012 Feb 9.
4. Chen Y., Hu F., Zhou Y., Chen W., Shao H., Zhang Y. MGMT promoter methylation and glioblastoma prognosis: A systematic review and meta-analysis. Arch. Med. Res. 2013, 44(4):281-290. (May). 10.1016/j.arcmed.2013.04.004. Epub 2013 Apr 19.
5. Combs E.S., Rieken S., Wick W., Abdollahi A., von Deimling A., Debus J., Hartmann C. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?. Radiat. Oncol. 2011, 13(6):115. (Sep). 10.1186/1748-717X-6-115.
6. Dahlrot R.H., Kristensen B.W., Hjelmborg J., Herrstedt J., Hansen S. A population based study of high grade gliomas and mutated isocitrate dehydrogebase 1. Int. J. Clin. Exp. Pathol. 2013, 6(1):31-40. (Epub 2012 Nov 20.).
7. Derks S., Lentjes M.H., Hellebrekers D.M., de Bruïne A.P., Herman J.G., van Engeland M. Methylation-specific PCR unraveled. Cell. Oncol. 2004, 26(5-6):291-299.
8. El Hindy N., Rump K., Labbertz N., Zhu Y., Frey U.H., Bankfalvi A., Siffert W., Sure U., Peters J., Adamzik M., Sandalcioglu I.E. The functional Aquporin 1-783G/C-polymorphism is associated with survival in patients with gliablastoma multiforme. J. Surg. Oncol. 2013, 108(7):492-498. (Dec). 10.1002/jso.23421. Epub 2013 Sep 6.
9. Hartman C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., Weller M., Herold-Mende C., Unterberg A., Jeuken J.W., Wesseling P., Reifenberger G., von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009, 118(4):469-474. (Oct). 10.1007/s00401-009-0561-9. Epub 2009 Jun 25.
10. Håvik A.B., Brandal P., Honne H., Dahlback H.S.S., Scheie D., Hektoen M., Meling T.R., Helseth E., Heim S., Lothe R., Lind G.E. MGMT promoter methylation in gliomas assessment by pyrosequencing and quantitative methylation-specific PCR. J. Transl. Med. 2012, 10:36. (Mar 6). 10.1186/1479-5876-10-36.
11. Ichimura K., Pearson D.M., Kocialkowski S., Bäcklund L.M., Chan R., Jones D.T., Collins V.P. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009, 11(4):341-347. (Aug, Epub 2009 May 12). 10.1215/15228517-2009-025.
12. Kim Y.H., Nobusawa S., Mittelbronn M., Paulus W., Brokinkel B., Keyvani K., Sure U., Wrede K., Nakazato Y., Tanaka Y., Vital A., Mariani L., Stawski R., Watanabe T., De Girolami U., Kleihues P., Ohgaki H. Molecular classification of low grade diffuse gliomas. Am. J. Pathol. 2010, 177(6):2708-2714. (Dec). 10.2353/ajpath.2010.100680. Epub 2010 Nov 12.
13. Krell D., Assoku M., Galloway M., Mulholland P., Tomlinson I., Bardella C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One 2011, 6(5):e19868. (Epub 2011 May 23.). 10.1371/journal.pone.0019868.
14. Ming-dong W., Yafang S., Hong W., Jiliang W., Wen-bin M., Ren-zhi W. Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme. Chin. Med. J. (Engl.) 2011, 124(17):2611-2615. (Sep).
15. Molenaar R.J., Verbaan D., Lamba S., Zanon C., Jeuken J.W., Boots-Spreger S.H., Wesseling P., Hulsebots T.J., Troost D., van Tilborg A.A., Leenstra S., Vandertop W.P., Bardelli A., van Noorden C.J., Bleeker F.E. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 2014, 16(9):1263-1273. (Sep). 10.1093/neuonc/nou005. Epub 2014 Feb 6.
16. Mulholland S., Pearson D.M., Hamoudi R.A., Malley D.S., Smith C.M., Weaver J.M., Jones D.T., Kocialkowski S., Bäcklund L.M., Collins V.P., Ichimura K. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. Int. J. Cancer 2012, 131(5):1104-1113. (Sep 1). 10.1002/ijc.26499. Epub 2012 Jan 11.
17. Nobusawa S., Watanabe T., Kleihues P., Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res. 2009, 15(19):6002-6007. (Oct 1, Epub 2009 Sep 15.). 10.1158/1078-0432.CCR-09-0715.
18. Olar A., Raghunathan A., Albarracin C.T., Aldape D.K., Cahill P.D., Powell Z.S., Goodman C.J., Fuller N.G. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Ann. Diagn. Pathol. 2012, 16(3):161-170. (Jun, Epub 2011 Dec 24.). 10.1016/j.anndiagpath.2011.08.010.
19. Ostrom Q.T., Gittleman H., Liao P., Rouse C., Chen Y., Dowling J., Wolinsky Y., Kruchko C., Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014, 16(suppl. 4):iv1-iv63. (Oct).
20. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321(5897):1807-1812. Sep 26. 10.1126/science.1164382. Epub 2008 Sep 4.
21. Pojo M., Costa B.M. Molecular hallmarks of gliomas. In Tech 2011, 177-200. M. Garami (Ed.).
22. Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., El Hallani S., Boisselier B., Mokhtar K., Hoang-Xuan K., Delattre J.Y. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 2009, 27(25):4150-4154. (Sep 1). 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.
23. Sonoda Y., Kumabe T., Nakamura T., Saito R., Kanamori M., Yamashita Y., Suzuki H., Tominaga T. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009, 100(10):1996-1998. (Oct). 10.1111/j.1349-7006.2009.01270.x.
24. Tost J., Gut I.G. DNA methylation analysis by pyrosequencing. Nat. Protoc. 2007, 2(9):2265-2275.
25. Uno M1., Oba-Shinjo S.M., Rd Silva, Miura F., Clara C.A., Almeida J.R., Malheiros S.M., Bianco A.M., Brandt R., Ribas G.C., Feres H., Dzik C., Rosemberg S., Stavale J.N., Teixeira M.J., Marie S.K. IDH1 mutations in a Brazilian series of glioblastoma. Clinics (Sao Paulo) 2011, 66(1):163-165.
26. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 2009, 174(4):1149-1153. (Apr, Epub 2009 Feb 26.). 10.2353/ajpath.2009.080958.
27. Wojdacz T.K., Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007, 35(6):e41. (Epub 2007 Feb 8.).
28. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360(8):765-773. (Feb 19). 10.1056/NEJMoa0808710.
29. Yan W., Zhang W., You G., Bao Z., Wang Y., Liu Y., Kang C., You Y., Wang L., Jiang T. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One 2012, 7(1):e30339. 10.1371/journal.pone.0030339. Epub 2012 Jan 23.